I-Corps: A novel gene assay for accurate prognosis and prediction of clinical benefits of chemotherapy for early-stage non-small cell lung cancer

I-Corps：一种新型基因检测，用于准确预后和预测早期非小细胞肺癌化疗的临床益处

• 批准号: 2221895
• 负责人: Nancy Guo
• 金额: $ 5万
• 依托单位: West Virginia University Research Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2023-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2221895&HistoricalAwards=false
• 关键词: Corps; novel; gene; assay; accurate

The broader impact/commercial potential of this I-Corps project is the development of an assay that addresses the high incidence of tumor recurrence in patients with non-small cell lung cancer (NSCLC) at the time of primary tumor surgical resection. The product may become part of the standard of care for stage 1 NSCLC patients at the time of surgical resection of the primary tumor, and be used to identify those at high-risk who would benefit from early implementation of chemotherapy to prevent tumor progression and recurrence. Clinical application of the proposed 7-gene assay may improve patient care and outcomes for those with lung cancer and reduce healthcare costs for the payers resulting from the failure of initial treatment.This I-Corps project is based on the development of a 7-gene marker panel that accurately predicts the risk of recurrence in early-stage NSCLC patients for all histological subtypes. Employing novel artificial intelligence (AI) methods, the assay also predicts the clinical benefits of receiving adjuvant chemotherapy in both proof-of-concept training and validation sample sets. This 7-gene assay may identify high-risk early-stage NSCLC patients following primary tumor resection for cancer recurrence, inform oncologists of the risk of recurrence to improve patient management, and recommend early implementation of platinum-based chemotherapy for high-risk stage 1 NSCLC patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

I-Corps项目更广泛的影响/商业潜力是开发一种检测方法，解决非小细胞肺癌（NSCLC）患者在原发肿瘤手术切除时肿瘤复发率高的问题。该产品可能成为1期NSCLC患者手术切除原发肿瘤时的标准护理的一部分，并用于识别那些将受益于早期实施化疗以防止肿瘤进展和复发的高危患者。建议的7基因检测的临床应用可以改善肺癌患者的护理和预后，并减少因初始治疗失败而导致的支付者的医疗费用。I-Corps项目基于7基因标记面板的开发，该面板可准确预测所有组织学亚型的早期NSCLC患者的复发风险。采用新颖的人工智能（AI）方法，该分析还预测了在概念验证训练和验证样本集中接受辅助化疗的临床益处。这项7基因检测可以识别原发性肿瘤切除术后复发的高危早期NSCLC患者，告知肿瘤学家复发风险以改善患者管理，并建议高危1期NSCLC患者早期实施铂类化疗。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

项目成果

Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks.

• DOI: 10.3390/biom12121782
• 发表时间: 2022-11-29
• 期刊: Biomolecules
• 影响因子: 5.5

MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer.

• DOI: 10.3390/cells12141917
• 发表时间: 2023-07-23
• 期刊: CELLS
• 影响因子: 6
• 作者: Ye, Qing;Raese, Rebecca A.;Luo, Dajie;Feng, Juan;Xin, Wenjun;Dong, Chunlin;Qian, Yong;Guo, Nancy Lan
• 通讯作者: Guo, Nancy Lan

Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer.

• DOI: 10.3390/ijms241310561
• 发表时间: 2023-06-23
• 期刊: International journal of molecular sciences
• 影响因子: 5.6